MX2022013301A - Métodos y composiciones para tratar las afecciones inflamatorias asociadas con una enfermedad infecciosa. - Google Patents

Métodos y composiciones para tratar las afecciones inflamatorias asociadas con una enfermedad infecciosa.

Info

Publication number
MX2022013301A
MX2022013301A MX2022013301A MX2022013301A MX2022013301A MX 2022013301 A MX2022013301 A MX 2022013301A MX 2022013301 A MX2022013301 A MX 2022013301A MX 2022013301 A MX2022013301 A MX 2022013301A MX 2022013301 A MX2022013301 A MX 2022013301A
Authority
MX
Mexico
Prior art keywords
compositions
conditions associated
methods
infectious disease
inflammatory conditions
Prior art date
Application number
MX2022013301A
Other languages
English (en)
Inventor
Timothy Alexander Moseley
Kenneth Allen Pettine
Kevin Hicok
Original Assignee
Direct Biologics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Direct Biologics Llc filed Critical Direct Biologics Llc
Publication of MX2022013301A publication Critical patent/MX2022013301A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/366—Thrombomodulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Endocrinology (AREA)

Abstract

Se divulgan en la presente composiciones que comprenden una preparación de células madre mesenquimales (MSC) y una o más biomoléculas y el uso de dichas composiciones para el tratamiento de una infección microbiana o los síntomas o las afecciones patológicas secundarias asociados con dicha infección.
MX2022013301A 2020-04-22 2021-04-22 Métodos y composiciones para tratar las afecciones inflamatorias asociadas con una enfermedad infecciosa. MX2022013301A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063013865P 2020-04-22 2020-04-22
US202063198706P 2020-11-06 2020-11-06
PCT/US2021/028686 WO2021216903A1 (en) 2020-04-22 2021-04-22 Methods and compositions for treating inflammatory conditions associated with infectious disease

Publications (1)

Publication Number Publication Date
MX2022013301A true MX2022013301A (es) 2023-02-14

Family

ID=78270105

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013301A MX2022013301A (es) 2020-04-22 2021-04-22 Métodos y composiciones para tratar las afecciones inflamatorias asociadas con una enfermedad infecciosa.

Country Status (11)

Country Link
US (2) US12590310B2 (es)
EP (1) EP4138867A4 (es)
JP (1) JP2023523588A (es)
KR (1) KR20230004709A (es)
CN (1) CN115843253A (es)
AU (2) AU2021261384B2 (es)
BR (1) BR112022021445A2 (es)
CA (1) CA3180973A1 (es)
IL (1) IL297563A (es)
MX (1) MX2022013301A (es)
WO (1) WO2021216903A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3801028A4 (en) 2018-05-30 2022-04-13 Direct Biologics LLC A growth factor and extracellular vesicle frozen or powdered additive comprising a mesenchymal stem cell (msc) preparation and methods of use
IL320107A (en) 2019-02-07 2025-06-01 Direct Biologics Llc Method for treating osteoarthritis with a combination of mesenchymal stem cell exosomes, synovial mesencymal stem cells, and scaffolds
WO2021011935A1 (en) 2019-07-18 2021-01-21 Direct Biologics, Llc Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use
MX2022013301A (es) 2020-04-22 2023-02-14 Direct Biologics Llc Métodos y composiciones para tratar las afecciones inflamatorias asociadas con una enfermedad infecciosa.
KR102317052B1 (ko) * 2020-05-04 2021-10-25 주식회사 티에스셀바이오 태반 유래의 세포외 소포의 항염증 항바이러스 효과 조성물
CN113789333B (zh) * 2021-09-07 2023-07-14 中国人民解放军军事科学院军事医学研究院 Chi3l1在调控hUC-MSCs抑制Th17分化介导的免疫调节作用上的应用
US20250034657A1 (en) 2021-12-21 2025-01-30 Kansai Medical University Educational Corporation Method for screening tuberculosis-infected sample and probe set to be used therefor
CN114469996B (zh) * 2021-12-23 2023-10-20 中国医学科学院医学生物学研究所 一种包含miR-135b-5p的外泌体及在抗轮状病毒感染中的应用
EP4499122A4 (en) * 2022-03-29 2026-07-01 Direct Biologics Llc RNA COMPRISING SECRETOMES AND THEIR METHODS OF USE
CN115478117A (zh) * 2022-05-11 2022-12-16 江苏命码生物科技有限公司 一种用于早期预警新型冠状病毒中重型、危重型病例的试剂盒
US11878036B2 (en) 2022-05-25 2024-01-23 Neuvian LLC Vaginal care compositions and methods of improving vaginal health
JP7406059B1 (ja) * 2022-10-20 2023-12-27 防衛装備庁長官 急性ストレス評価用データの生成方法
CN116656699B (zh) * 2023-05-16 2024-05-31 南京农业大学 SESN2和chi-miR-130b-3p在调节由玉米赤霉烯酮诱导的颗粒细胞凋亡中的应用
CN116515995B (zh) * 2023-06-29 2023-09-19 迈杰转化医学研究(苏州)有限公司 一种检测噬血细胞性淋巴组织细胞增生症的血清microRNA标志物及其应用
CN116875550B (zh) * 2023-09-08 2023-12-26 天津市肿瘤医院（天津医科大学肿瘤医院） 一种FABP4+C1q+巨噬细胞及其制备方法和用途
WO2025226276A1 (en) * 2024-04-25 2025-10-30 Direct Biologics, Llc Treatment of fistula with bone marrow mesenchymal stem cell derived extracellular vesicles
CN118459570B (zh) * 2024-07-10 2024-11-12 南京领源生物科技有限公司 一种能改善胰岛素分泌和增殖功能的多肽pdmhs2
CN118909053B (zh) * 2024-10-11 2025-01-28 南京农业大学三亚研究院 抗菌肽或其盐、药物组合物及应用
CN121930367B (zh) * 2026-02-03 2026-07-17 安康市中心医院 基于Th17免疫轴调控的双特异性融合蛋白及其在炎症性肠病与银屑病联合治疗中的应用

Family Cites Families (214)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1601438A (es) 1968-10-17 1970-08-24
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
CA2018228C (en) 1989-06-05 1996-02-27 Nancy L. Parenteau Cell culture systems and media
US5135917A (en) 1990-07-12 1992-08-04 Nova Pharmaceutical Corporation Interleukin receptor expression inhibiting antisense oligonucleotides
DE69922933T2 (de) 1998-03-13 2005-12-29 Osiris Therapeutics, Inc. Anwendungen für humane nicht autologe, mesenchymale stammzellen
GB9807639D0 (en) 1998-04-14 1998-06-10 Kennedy Rheumatology Inst Anti-inflammatory agents
FR2785543B1 (fr) 1998-11-05 2003-02-28 Inst Nat Sante Rech Med Exosomes modifies et utilisations
US6372494B1 (en) 1999-05-14 2002-04-16 Advanced Tissue Sciences, Inc. Methods of making conditioned cell culture medium compositions
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
AU2002353907A1 (en) 2001-10-26 2003-06-30 Steven A. Baranowitz Methods for treating wounds using melanin and related substances
DE10224982A1 (de) 2002-06-05 2003-12-24 Rolf Hoffmann Mesenchymale Stammzellen des Haarfollikels und deren Verwendung
US20040248970A1 (en) 2003-04-10 2004-12-09 Webster G.R. Barrie CBD-delta8-THC composition
ES2569780T3 (es) 2003-06-27 2016-05-12 DePuy Synthes Products, Inc. Células posparto derivadas de tejido placentario y métodos de preparación y uso de las mismas
WO2006036213A2 (en) 2004-04-29 2006-04-06 Pediamed Pharmaceuticals, Inc. The use of gammaglobulin for the treatment of periodontal disease
KR100668371B1 (ko) 2004-12-30 2007-01-12 한훈 제대혈 유래 줄기세포를 이용한 대머리 치료
US20080241112A1 (en) 2005-05-10 2008-10-02 Christof Westenfelder Therapy of Kidney Diseases and Multiorgan Failure with Mesenchymal Stem Cells and Mesenchymal Stem Cell Conditioned Media
CA2619593C (en) 2005-08-19 2018-12-11 Duke University Stem cell derived factors for treating pathologic conditions
US20070254827A1 (en) 2006-04-27 2007-11-01 The Regents Of The University Of California Alpha-aminobenzyl-alpha,alpha,-diphosphoric acid selective chelation of beryllium
US20090304644A1 (en) 2006-05-30 2009-12-10 Cytori Therapeutics, Inc. Systems and methods for manipulation of regenerative cells separated and concentrated from adipose tissue
WO2007149548A2 (en) 2006-06-22 2007-12-27 Medistem Laboratories, Inc. Treatment of erectile dysfunction by stem cell therapy
WO2008023829A1 (en) 2006-08-22 2008-02-28 National University Corporation Tokyo Medical And Dental University Application of synovium-derived mesenchymal stem cells (mscs) for cartilage or meniscus regeneration
WO2008024996A2 (en) 2006-08-24 2008-02-28 Johnstone Brian H Production of neural protective and regenerative factors from stem cells and treatment of nervous system conditions therewith
NZ586497A (en) 2008-01-04 2012-07-27 Lydac Neuroscience Ltd Microvesicles
US20090177487A1 (en) 2008-01-07 2009-07-09 Tera Eerkes Methods for Assessing Genetic Compatibility
PT2254586E (pt) 2008-02-22 2015-05-18 Agency Science Tech & Res Partículas de células estaminais mesenquimais
CN102119031B (zh) 2008-06-11 2014-09-10 弗雷森纽斯医疗护理德国有限责任公司 肝祖细胞的条件培养基
CA2756670A1 (en) 2009-03-26 2010-09-30 The Regents Of The University Of California Mesenchymal stem cells producing inhibitory rna for disease modification
JP2012528809A (ja) 2009-06-05 2012-11-15 スキンレップヘア・リミテッド 老化した皮膚の再生のための毛根鞘由来幹細胞およびケラチノサイト前駆細胞の使用
US9642817B2 (en) 2009-08-27 2017-05-09 Technion Research & Development Foundation Limited Liposomal compositions and uses of same
US8778416B2 (en) 2010-02-10 2014-07-15 Nayacure Therapeutics Ltd. Pharmaceutical compositions and methods for the treatment and prevention of cancer
US20130195991A1 (en) 2010-03-26 2013-08-01 National University Corporation Nagoya University Composition for Treatment of Damaged Part
WO2011160055A2 (en) 2010-06-18 2011-12-22 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Hair follicle neogenesis
PT2621488T (pt) 2010-09-29 2019-02-12 Pulmatrix Operating Co Inc Pós secos catiónicos
PT2635299T (pt) 2010-11-02 2019-10-14 Univ Columbia Métodos de tratamento de distúrbios de perda de cabelo
US20140004601A1 (en) 2010-12-20 2014-01-02 Agency For Science, Technology And Research Method of purifying exosomes
KR102063069B1 (ko) 2011-03-11 2020-01-08 칠드런'즈 메디컬 센터 코포레이션 중간엽 줄기 세포 엑소솜에 관련된 방법 및 조성물
WO2012142569A2 (en) 2011-04-15 2012-10-18 The Regents Of The University Of California Decellularized extracellular matrix
EP2721179A4 (en) 2011-06-16 2014-10-01 Caris Life Sciences Luxembourg Holdings S A R L BIOMARKER COMPOSITIONS AND METHOD THEREFOR
US8494123B2 (en) 2011-07-01 2013-07-23 Apple Inc. On-hold visual menu from a user's communications device
ITRM20110403A1 (it) 2011-07-28 2013-01-29 Ospedale Pediatrico Bambino Gesu Microvescicole isolate da cellule mesenchimali come agenti immunosoppressori.
JP6215216B2 (ja) 2011-10-27 2017-10-18 ウニヴェルジテート ライプチッヒ 毛包外毛根鞘からメラノサイトを誘導する方法および移植のための調製
US20130129688A1 (en) 2011-11-09 2013-05-23 Allocure, Inc. Assay for the Prediction of Therapeutic Effectiveness or Potency of Mesenchymal Stem Cells, and Methods of Using Same
ES2661236T3 (es) 2011-12-13 2018-03-28 Henry Ford Health System Procedimientos, sistemas y composiciones para administración de microARN derivado de células/a base de vesículas
US9427450B2 (en) 2012-01-31 2016-08-30 Xon Cells, Inc. Therapeutic immune modulation by stem cell secreted exosomes
KR20150009521A (ko) 2012-03-07 2015-01-26 파이브로셀 테크놀로지스, 인코퍼레이티드 국소피부제제 및 개인맞춤형 피부치료방법
EP3470073A1 (en) 2012-04-03 2019-04-17 Reneuron Limited Stem cell microparticles
CN107083385A (zh) 2012-04-20 2017-08-22 艾珀特玛治疗公司 产热的miRNA调节剂
EP2850178A4 (en) 2012-05-18 2015-10-28 Agency Science Tech & Res MESENCHYMAL NAIL STAMMING CELL EXOSOME
JP6273272B2 (ja) 2012-07-04 2018-01-31 ジージー バイオテック エルエルシー 炎症性皮膚障害の治療
EP2687219A1 (en) 2012-07-18 2014-01-22 Universität Duisburg-Essen Use of preparations comprising exosomes derived from mesenchymal stem cells (MSCs) in the prevention and therapy of inflammatory conditions
SG11201500329WA (en) 2012-07-19 2015-02-27 Reneuron Ltd Stem cell microparticles
CU24121B1 (es) 2012-08-02 2015-08-27 Ct De Ingeniería Genética Y Biotecnología Vesículas que comprenden factor de crecimiento epidérmico y composiciones que las contienen
EP3563859B1 (en) 2012-08-13 2021-10-13 Cedars-Sinai Medical Center Cardiosphere-derived exosomes for tissue regeneration
US20150366997A1 (en) 2012-12-07 2015-12-24 Shire Human Genetics Therapies, Inc. COMPOSITIONS AND METHODS FOR mRNA DELIVERY
US9408874B2 (en) 2013-02-15 2016-08-09 Kenneth Allen Pettine Regenerative autologous bone marrow cell therapies and methods for their use in the treatment of joint pain
WO2015023901A1 (en) 2013-08-15 2015-02-19 The Regents Of The University Of California Placenta-derived multipotent stem cells
WO2015031110A2 (en) 2013-08-27 2015-03-05 The Regents Of The University Of California Combination therapy to promote wound healing
KR20160073382A (ko) 2013-10-04 2016-06-24 셀 아이디어스 피티와이 엘티디 세포 치료를 위한 바이오마커들
GB2520300A (en) 2013-11-15 2015-05-20 Univ Loughborough Cell Culture System
CN107075568A (zh) 2014-05-01 2017-08-18 阿姆斯特丹自由大学医学中心基金会 作为生物标记物的小ncRNA
US20170304368A1 (en) 2014-10-06 2017-10-26 Cedars-Sinai Medical Center Polarization of macrophages to a healing phenotype by cardiosphere-derived cells and by the exosomes secreted by such cells
WO2016082882A1 (en) 2014-11-27 2016-06-02 Med Cell Europe Ag Secretomes and method for producing secretomes
RU2644650C2 (ru) 2014-12-01 2018-02-13 Общество с ограниченной ответственностью "Т-Хелпер Клеточные Технологии" Материал стволовых клеток и способ его получения
CN104622904A (zh) 2015-02-05 2015-05-20 山西医科大学 一种皮肤干细胞活性成分及其应用
WO2016149358A1 (en) 2015-03-16 2016-09-22 Duncan Ross Method of treatment comprising membrane-enclosed vesicle
GB201505747D0 (en) 2015-04-02 2015-05-20 Univ Bristol Exosomes
EP3286318A2 (en) 2015-04-22 2018-02-28 Mina Therapeutics Limited Sarna compositions and methods of use
CA2986310A1 (en) 2015-05-11 2016-11-17 Editas Medicine, Inc. Optimized crispr/cas9 systems and methods for gene editing in stem cells
WO2017001649A1 (en) 2015-07-02 2017-01-05 Med Cell Europe Ag Secretomes and method for producing secretomes
CN111150743A (zh) 2018-11-06 2020-05-15 中国医药大学 间质干细胞在治疗多发性硬化症的用途
CA2993955A1 (en) 2015-07-29 2017-02-02 Indiana University Research And Technology Corporation Materials and methods for treating and evaluating ischemic and/or reperfusion-injured tissue and/or tissue susceptible to same
HRP20230865T1 (hr) 2015-07-31 2023-11-10 Exotropin, Llc Kompozicije egzosoma i postupci za njihovu pripremu i primjenu za reguliranje i kondicioniranje kože i kose
WO2017066663A1 (en) 2015-10-15 2017-04-20 Carromeu Cassiano Method of manufacturing cells using a hollow fiber bioreactor
KR102311832B1 (ko) 2015-10-16 2021-10-13 (주)프로스테믹스 줄기세포 유래 엑소좀을 포함하는 상처 치료, 피부 개선 및 탈모 방지 또는 치료용 조성물 및 그 제조방법
KR101765767B1 (ko) 2015-11-02 2017-08-07 희성촉매 주식회사 담체 계면 공극 집중 매몰형 scr 촉매 구조체
US20170121685A1 (en) 2015-11-02 2017-05-04 Tigenix S.A.U. Mesenchymal stem cell-derived exosomes and their uses
WO2017117585A1 (en) 2015-12-30 2017-07-06 The Regents Of The University Of California Methods for enhanced production and isolation of cell-derived vesicles
WO2017123022A1 (ko) 2016-01-12 2017-07-20 주식회사 강스템바이오텍 고함량의 성장인자를 함유한 줄기세포 유래 엑소좀
US11918687B2 (en) 2016-01-15 2024-03-05 Orbsen Therapeutics Limited SDC-2 exosome compositions and methods of isolation and use
EP3414320A1 (en) 2016-02-12 2018-12-19 Cell Care Therapeutics Adipose tissue derived mesenchymal stromal cell conditioned media and methods of making and using the same
WO2017147536A1 (en) 2016-02-24 2017-08-31 The Rockefeller University Embryonic cell-based therapeutic candidate screening systems, models for huntington's disease and uses thereof
US20190000886A1 (en) * 2016-03-16 2019-01-03 Duncan ROSS Method of treatment of osteochondral defects
JP2017180553A (ja) 2016-03-29 2017-10-05 トヨタ自動車株式会社 動力伝達装置
WO2017196798A1 (en) 2016-05-09 2017-11-16 Chang Jae-Hyung Robert Accelerated method for preparing platelet rich plasma
RU2708329C2 (ru) 2016-05-31 2019-12-05 Общество с ограниченной ответственностью "Т-Хелпер Клеточные Технологии" Материал стволовых клеток, композиции и способы применения
AU2017286656A1 (en) 2016-06-15 2019-01-17 Ojai Energetics Pbc Methods and compositions for potentiating stem cell therapies
AU2017301035A1 (en) 2016-07-18 2019-02-07 Brainstorm Cell Therapeutics Ltd Methods for treating amyotrophic lateral sclerosis (ALS)
JP6918943B2 (ja) 2016-07-29 2021-08-11 ラ，チョンチャン 癌細胞の増殖を抑制する間葉幹細胞の製造方法
KR101977019B1 (ko) 2016-08-26 2019-05-10 연세대학교 산학협력단 중간엽 줄기세포 유래 분비 단백체를 포함하는 류마티스 관절염 치료용 약제학적 조성물 및 이를 이용한 치료 방법
WO2018044795A1 (en) 2016-08-29 2018-03-08 Yong Zhao Compositions and methods for programming adult cells with platelet rich fraction of blood containing platelet-like cells
AU2017321314A1 (en) 2016-08-29 2019-02-28 Hackensack University Medical Center Compositions and methods for reprogramming adult cells through the stemness of a platelet rich fraction of blood containing platelet-like cells in humans
EP3515474B1 (en) 2016-09-19 2026-03-04 Cambridge Innovation Technologies Consulting Limited Human asparaginase lacking glutaminase activity
US12161111B2 (en) 2016-09-23 2024-12-10 Peter Friedman Compositions and methods for treating citrus plants infected with bacteria and for promoting general agricultural health
US9980984B2 (en) 2016-10-13 2018-05-29 Kenneth Allen Pettine Treatment of inflammation of osteoarthritic knees with mesenchymal stem cells
IT201600109148A1 (it) 2016-10-28 2018-04-28 Pharmaexceed Srl Processo per isolare e liofilizzare vescicole extracellulari
AU2017354272A1 (en) 2016-11-03 2019-05-23 Exostem Biotec Ltd. Mesenchymal stem cells populations, their products, and use thereof
WO2018102696A1 (en) 2016-12-02 2018-06-07 Vmr Products Llc Vaporizer
US20180318356A1 (en) 2016-12-29 2018-11-08 Kenneth Allen Pettine Dermatological and cosmetic treatments using mesenchymal stem cells
WO2018130554A1 (en) 2017-01-11 2018-07-19 Paracelsus Medizinische Privatuniversität Salzburg - Privatstiftung Mesenchymal stem cell-derived extracellular vesicles and their medical use
US20190330594A1 (en) 2017-01-11 2019-10-31 Stemlab Inc. Method for preparing composition, included within exosome obtained from nanog-introduced, fetus-derived mesenchymal stem cell in amniotic fluid, for hair growth
JP2020505345A (ja) 2017-01-16 2020-02-20 セルズ フォー セルズ エセ．アー． 乏血小板血漿（ｐｐｐ）に封入された実質的に純粋な多能性間質細胞集団を含む組成物
US10987381B2 (en) 2017-01-27 2021-04-27 Neil Riordan Mesenchymal stem cells with enhanced efficacy in treatment of autoimmunity particularly rheumatoid arthritis
JP7225104B2 (ja) 2017-02-01 2023-02-20 ジービーエス グローバル バイオファーマ，インコーポレイテッド マスト細胞関連炎症障害又は好塩基球媒介炎症障害の治療のためのカンナビノイド含有複合混合物
MY196026A (en) 2017-02-16 2023-03-07 Oct Therapies And Res Private Limited Stem Cell Conditioned Media for Clinical and Cosmetic Applications
WO2018162696A1 (en) 2017-03-10 2018-09-13 Institut Pasteur Common genetic variations at the tcra-tcrd locus control thymic function in humans
US20180264043A1 (en) 2017-03-14 2018-09-20 Holding Pen, Llc Restoration of deteriorated tissue in the face or selected areas of the body with mesenchymal stem cells
US20180338866A1 (en) 2017-03-21 2018-11-29 Mohammad Ali Kharazmi Electroactive dressings
US20210254056A1 (en) 2017-05-05 2021-08-19 Camp4 Therapeutics Corporation Identification and targeted modulation of gene signaling networks
US11529376B2 (en) 2017-05-05 2022-12-20 Capricor, Inc. Methods of treating systemic graft-versus-host disease with extracellular vesicles
US20200392219A1 (en) 2017-05-08 2020-12-17 Trustees Of Tufts College Extracellular vesicles comprising membrane-tethered tgf-beta, compositions and methods of use thereof
US20200188440A1 (en) 2017-05-16 2020-06-18 Exostem Biotec Ltd. Methods of inhibiting aging and treating aging-related disorders
WO2018226758A2 (en) 2017-06-05 2018-12-13 The Regents Of The University Of California Methods for enhanced production and isolation of cell-derived vesicles and treatment of inflammation and neurological damage
AU2018316603B2 (en) * 2017-08-15 2024-06-13 Children's Medical Center Corporation Purified mesenchymal stem cell exosomes and uses thereof
CA3073879A1 (en) 2017-08-24 2019-02-28 The Texas A&M University System Mesenchymal stem/stromal cell-derived extracellular vesicles and uses thereof in autoimmune diseases
CN119552810A (zh) * 2017-11-16 2025-03-04 细胞结构公司 用以分离外泌体的胎盘培养
US12036325B2 (en) 2017-12-14 2024-07-16 Mayo Foundation For Medical Education And Research Purified exosome products, method of making, and methods of using
US11660355B2 (en) 2017-12-20 2023-05-30 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
CN108042572A (zh) 2017-12-27 2018-05-18 北京多赢时代转化医学研究院 治疗白癜风的产品及其使用方法和应用
EP3740576A4 (en) 2018-01-18 2021-10-20 Advanced Regen Medical Technologies, LLC THERAPEUTIC COMPOSITIONS AND THEIR PREPARATION AND USE METHODS
WO2019152522A1 (en) 2018-01-30 2019-08-08 Histogen, Inc. Extracellular vesicles derived from cells cultured under hypoxic conditions and uses thereof
CN108456655A (zh) 2018-02-23 2018-08-28 深圳至博生物科技有限公司 间充质干细胞悬浮液及其制备方法与应用
US20210000882A1 (en) 2018-02-28 2021-01-07 Crown Scientific, LLC Production and use of extracellular vesicles
WO2019198077A1 (en) 2018-04-10 2019-10-17 Brainstorm Cell Therapeutics Ltd. Cell-type specific exosomes and use thereof
CN108498452A (zh) 2018-04-10 2018-09-07 上海交通大学医学院附属仁济医院 一种用于治疗勃起功能障碍的含干细胞可注射水凝胶及其制备方法
WO2019217091A1 (en) 2018-04-30 2019-11-14 Children's Medical Center Corporation Mesenchymal stromal cell exosomes and uses thereof
EP3813896B1 (en) 2018-05-14 2025-10-01 Roosterbio, Inc. Methods and compositions related to extracellular material derived from hypertonic cell solutions
EP3801028A4 (en) 2018-05-30 2022-04-13 Direct Biologics LLC A growth factor and extracellular vesicle frozen or powdered additive comprising a mesenchymal stem cell (msc) preparation and methods of use
JPWO2019235362A1 (ja) 2018-06-08 2021-07-08 カノンキュア株式会社 線維化抑制組成物、これを生産する細胞、およびこの細胞からなる細胞シート
US20230142496A1 (en) 2018-06-18 2023-05-11 North Carolina State University Stem cell biomimetic nanoparticle therapeutic agents and uses thereof
US20200030253A1 (en) 2018-07-26 2020-01-30 Mohammad Ali Kharazmi Methods and compositions for treatment of body conditions
US20210228643A1 (en) 2018-07-26 2021-07-29 Uniwersytet Jagiellonski N vivo delivery system of the genome dna modifying enzymes and the use thereof
KR102163806B1 (ko) 2018-07-30 2020-10-07 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피지분비 감소용 조성물
WO2020028526A1 (en) 2018-08-02 2020-02-06 Histogen, Inc. Conditioned medium and extracellular matrix compositions and uses thereof
EA202190474A1 (ru) 2018-08-08 2021-04-15 Терамир Лтд Терапия на основе микро-рнк, направленная против lcp-1-позитивных раковых опухолей
EP3841217A4 (en) 2018-08-24 2022-05-18 University Of Delaware EXTRACELLULAR VESICLES AS BIOMARKERS AND THERAPEUTICS FOR NEUROMUSCULAR DISEASES
EP3853347A4 (en) 2018-09-21 2022-06-29 Tarachon LLC Cartilage regeneration by synovial fluid-derived stem cells and their derivatives
WO2020069313A2 (en) 2018-09-28 2020-04-02 Henry Ford Health System Use of extracellular vesicles in combination with tissue plasminogen activator and/or thrombectomy to treat stroke
WO2020081859A1 (en) 2018-10-18 2020-04-23 Nantbio, Inc. Mesenchymal stem cell derived exosomes and methods
AU2019416339A1 (en) 2018-12-26 2021-07-22 Direct Biologics Llc Methods and compositions for treating skin and hair disorders
CA3125617A1 (en) 2019-01-04 2020-07-09 Kenneth Allen Pettine Isolation and use of autogenous platelet derived exosomes
CN109718392B (zh) 2019-01-18 2021-11-26 广州润虹医药科技股份有限公司 复合型医用敷料及其制备方法
AU2020214832A1 (en) 2019-01-30 2021-08-19 Direct Biologics Llc Methods and compositions for developing target specific exosome and growth factor products
IL320107A (en) 2019-02-07 2025-06-01 Direct Biologics Llc Method for treating osteoarthritis with a combination of mesenchymal stem cell exosomes, synovial mesencymal stem cells, and scaffolds
JP2022520505A (ja) 2019-02-07 2022-03-30 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 細胞外小胞（ｅｖ）除去培地を調製するための方法
US20220136011A1 (en) 2019-02-08 2022-05-05 Board Of Regents, The University Of Texas System Telomerase-containing exosomes for treatment of diseases associated with aging and age-related organ dysfunction
EP3927317A4 (en) 2019-02-19 2022-08-10 Direct Biologics, LLC ACELLULAR INTRAVENOUS INFUSION WITH GROWTH FACTORS FROM MESENCHYMAL STEM CELLS AND EXOSOMES
IT201900003639A1 (it) * 2019-03-13 2020-09-13 Evobiotech S R L Composizioni di vescicole extracellulari (EV) derivate da piante e loro usi
AU2020272767A1 (en) 2019-04-08 2021-11-11 SymbioCell Tech, LLC. Treatment of microvascular disorders with mesenchymal stem cells and their exosomes
US10758571B1 (en) 2019-04-09 2020-09-01 Combangio, Inc. Processes for making and using a mesenchymal stem cell derived secretome
US20220202871A1 (en) 2019-04-29 2022-06-30 Direct Biologics, Llc Method for the treatment of periodontal disease using characterized mesenchymal stem cell growth factors and exosomes
KR102049505B1 (ko) 2019-05-14 2019-11-29 이장호 젖산탈수소효소 b 및 페록시좀 증식인자-활성화 수용체 감마 활성화인자 1-알파가 함유된 면역관용화된 세포외소포의 제조방법 및 이를 이용한 항암용 조성물
CN117384828A (zh) 2019-06-10 2024-01-12 布瑞克斯奥根株式会社 用于促进干细胞来源外泌体产生和增加干性的包含透明质酸的组合物
CN114302731A (zh) 2019-06-19 2022-04-08 细胞结构公司 用于治疗疾病的外泌体
AU2020303456B2 (en) 2019-06-26 2026-01-08 Technion Research And Development Foundation Limited Production of extracellular vesicles from stem cells
WO2021009660A1 (en) 2019-07-12 2021-01-21 Vasanthi Palanivel Composition and methods for improving thickness and receptivity of endometrial lining
WO2021011935A1 (en) 2019-07-18 2021-01-21 Direct Biologics, Llc Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use
WO2021016368A1 (en) 2019-07-22 2021-01-28 Erivan Bio, Llc Topical exosome compositions and associated methods
CN114269358A (zh) 2019-07-31 2022-04-01 上海圣特佳健康科技发展有限公司 针对纤维化、炎症、和/或老化疾病的治疗药物
US11138804B2 (en) 2019-08-02 2021-10-05 Fmr Llc Intelligent smoothing of 3D alternative reality applications for secondary 2D viewing
AU2020383622A1 (en) 2019-11-15 2022-06-16 Secretome Therapeutics, Inc. Immortalized cardiac stem cells for cardiac repair
US20210169939A1 (en) 2019-12-04 2021-06-10 United Therapeutics Corporation Extracellular vesicles and their uses
US20230013636A1 (en) 2019-12-05 2023-01-19 Board Of Regents, The University Of Texas System Exosomes-based therapy for liver fibrosis and other diseases with fibrosis
CN113134014B (zh) 2020-01-20 2023-09-26 医微细胞生物技术(广州)有限公司 囊泡在制备血友病药物中的应用
EP4114923A1 (en) 2020-03-05 2023-01-11 MVEX Japan, Inc. Extracellular vesicle compositions and the use thereof in the treatment of skin conditions and in immune modulation
US20230105667A1 (en) 2020-03-12 2023-04-06 Exostem Biotec Ltd. Mesenchymal stromal cells and extracellular vesicles for treating viral infections, inflammation, and tissue fibrosis
US20230143893A1 (en) 2020-03-23 2023-05-11 Avem Holdings Llc Isolation and purification of exosomes for regenerative medicine
WO2021207282A2 (en) 2020-04-07 2021-10-14 Combangio, Inc. Lyophilized mesenchymal stem cell derived secretome and uses thereof
MX2022013301A (es) 2020-04-22 2023-02-14 Direct Biologics Llc Métodos y composiciones para tratar las afecciones inflamatorias asociadas con una enfermedad infecciosa.
KR102319735B1 (ko) 2020-04-28 2021-11-01 건국대학교 산학협력단 3차원 배양된 줄기세포로부터 세포외 소포체를 제조하는 방법
TW202146034A (zh) 2020-05-05 2021-12-16 美國商加速生物科學有限公司 包含有分泌蛋白體的藥學與化妝品組成物
JP2023531721A (ja) 2020-06-24 2023-07-25 カメレオン バイオサイエンシーズ， インコーポレイテッド 免疫モジュレーターを有する細胞外小胞
MX2023000226A (es) 2020-07-09 2023-02-23 Exo Biologics Sa Proceso para la fabricacion de vesiculas extracelulares asociadas a proteinas.
EP4178591A1 (en) 2020-07-09 2023-05-17 Exo Biologics Sa Extracellular vesicles and compositions thereof
WO2022008652A1 (en) 2020-07-09 2022-01-13 Exo Biologics Sa EXTRACELLULAR VESICLES (EVs) DERIVED FROM MESENCHYMAL STROMAL CELLS AND METHOD FOR OBTAINING SAID EVs
EP4181935A1 (en) 2020-07-20 2023-05-24 Brainstorm Cell Therapeutics Ltd. Methods and compositions for treating lung conditions
US20230313144A1 (en) 2020-09-03 2023-10-05 Jichi Medical University Detoxified secretome extract made from culture supernatant of mesenchymal stem cells or progenitor cells derived from the mesenchymal stem cells, and method for producing same
WO2022076419A1 (en) 2020-10-05 2022-04-14 Albert Einstein College Of Medicine Methods of treating viral infections with pirnas or extracellular vessicles released from neural stem cells or neural progenitor cells
US20220110970A1 (en) 2020-10-14 2022-04-14 The Texas A&M University System Engineered Extracellular Vesicle Delivery Systems and Uses Thereof
US20230414730A1 (en) 2020-11-06 2023-12-28 Aatec Medical Gmbh A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
WO2022150696A1 (en) 2021-01-11 2022-07-14 United Therapeutics Corporation Ev for use in treating myocarditis
WO2022174079A1 (en) 2021-02-12 2022-08-18 Modernatx, Inc. Lnp compositions comprising payloads for in vivo therapy
WO2022251167A2 (en) 2021-05-24 2022-12-01 University Of Pittsburgh – Of The Commonwealth System Of Higher Education Methods and materials for treating a stroke
WO2022265864A2 (en) 2021-06-04 2022-12-22 The Brigham And Women’S Hospital, Inc Tim-3 modulates anti-tumor immunity by regulating inflammasome activation
CA3221637A1 (en) 2021-06-09 2022-12-15 William MASLANIK Tissue extracts and related methods
EP4355304A4 (en) 2021-06-17 2025-04-30 Malcolm, Thomas PERSONALIZED HYPOIMMUNE NANOVESICULAR DELIVERY SYSTEMS FOR CANCERS, INHERITED DISEASES AND INFECTIOUS DISEASES
FR3124696B1 (fr) 2021-06-30 2025-03-14 Tbf Genie Tissulaire Materiau biologique imprégné de vesicules lipidiques
CA3224150A1 (en) 2021-07-02 2023-01-05 Combangio, Inc. Processes for making and using a cellular fibronectin composition
JP7803499B2 (ja) 2021-07-06 2026-01-21 コングク ユニバーシティ インダストリアル コーオペレーション コーポレーション 幹細胞由来細胞外小胞体及びその用途
WO2023281524A1 (en) 2021-07-06 2023-01-12 Suma Kantipudi Placenta derived mesenchymal stromal cell secretome, process and uses thereof
WO2023004087A2 (en) 2021-07-21 2023-01-26 Mercy Bioanalytics, Inc. Compositions and methods for cancer detection
WO2023021525A1 (en) 2021-08-16 2023-02-23 Lifecell International Pvt. Ltd A human amnion-chorion based wound dressing material and method thereof
WO2023024637A1 (zh) 2021-08-26 2023-03-02 中山大学 一种力学性囊泡的制备方法
KR102704051B1 (ko) 2021-08-30 2024-09-09 가톨릭대학교 산학협력단 세포 밖 소포체 함유 안표면 염증 질환 예방 또는 치료용 조성물
WO2023064555A1 (en) 2021-10-15 2023-04-20 The Board Of Trustees Of The Leland Stanford Junior University Cell-derived nanovesicles for in vivo transport and delivery of therapeutic materials
WO2023075557A1 (ko) 2021-10-29 2023-05-04 주식회사 씨케이엑소젠 연골 항상성 인자를 포함하는 엑소좀 및 이를 포함하는 골관절염 예방 또는 치료용 조성물
CA3237605A1 (en) 2021-11-12 2023-05-19 Darryl Raymond DAVIS Compositions of human heart derived extracellular vesicles and uses thereof
US20250032550A1 (en) 2021-11-16 2025-01-30 West Virginia University Board of Governors on behalf of West Virginia University A novel way for brain-specific delivery of molecules for the treatment of brain diseases
US20250057776A1 (en) 2021-12-28 2025-02-20 Sekisui Chemical Co., Ltd. Exosome, method of forming same, and composition containing same
WO2023123216A1 (zh) 2021-12-30 2023-07-06 中山大学 囊泡在制备治疗肺部疾病的药物中的应用
US20230226267A1 (en) 2022-01-19 2023-07-20 Semiflex Dome System Sp. Z.o.o. Dome catheter system for transcutaneous vacuum assisted closure of perianal or enterocutaneous abcesses and fistula tracts and method thereof
EP4499122A4 (en) 2022-03-29 2026-07-01 Direct Biologics Llc RNA COMPRISING SECRETOMES AND THEIR METHODS OF USE
WO2024192119A1 (en) 2023-03-14 2024-09-19 Direct Biologics, Llc Wound healing compositions and methods thereof
CN121729236A (zh) 2023-06-09 2026-03-24 迪瑞克特生物制剂有限责任公司 使用细胞外囊泡组合物的肌萎缩性侧索硬化症治疗
WO2024254459A2 (en) 2023-06-09 2024-12-12 Direct Biologics, Llc Treatment of complex regional pain syndrome with extracellular vesicle composition
CN122497513A (zh) 2023-11-07 2026-07-31 迪瑞克特生物制剂有限责任公司 使用细胞外囊泡组合物治疗经辐射的皮肤
CN122497512A (zh) 2023-11-07 2026-07-31 迪瑞克特生物制剂有限责任公司 使用细胞外囊泡组合物的腰椎小关节综合征治疗
WO2025101663A1 (en) 2023-11-07 2025-05-15 Direct Biologics, Llc Extracellular vesicle composition for use in the treatment of graft-versus-host disease
CN122514375A (zh) 2023-11-07 2026-08-04 迪瑞克特生物制剂有限责任公司 用于治疗长新冠的细胞外囊泡组合物
WO2025189128A1 (en) 2024-03-08 2025-09-12 Direct Biologics, Llc Treatment of infertility with extracellular vesicle composition
WO2025199333A1 (en) 2024-03-21 2025-09-25 Direct Biologics, Llc Treatment of ehlers-danlos syndrome with extracellular vesicle composition
WO2025226863A1 (en) 2024-04-24 2025-10-30 Direct Biologics, Llc Treatment of traumatic brain injury with extracellular vesicle composition
WO2025226866A1 (en) 2024-04-24 2025-10-30 Direct Biologics, Llc Bone marrow mesenchymal stem cell derived extracellular vesicles to improve perioral area and face fat graft retention
WO2025226276A1 (en) 2024-04-25 2025-10-30 Direct Biologics, Llc Treatment of fistula with bone marrow mesenchymal stem cell derived extracellular vesicles

Also Published As

Publication number Publication date
CN115843253A (zh) 2023-03-24
US20230159932A1 (en) 2023-05-25
EP4138867A4 (en) 2024-05-01
KR20230004709A (ko) 2023-01-06
US20250277217A1 (en) 2025-09-04
AU2025220828A1 (en) 2025-09-11
EP4138867A1 (en) 2023-03-01
AU2021261384B2 (en) 2025-08-14
CA3180973A1 (en) 2021-10-28
WO2021216903A1 (en) 2021-10-28
US12590310B2 (en) 2026-03-31
BR112022021445A2 (pt) 2023-01-10
US12570980B2 (en) 2026-03-10
IL297563A (en) 2022-12-01
JP2023523588A (ja) 2023-06-06
AU2021261384A1 (en) 2022-12-22

Similar Documents

Publication Publication Date Title
BR112022021445A2 (pt) Métodos e composições para tratar condições inflamatórias associadas com doença infecciosa
CO2022001210A2 (es) Conjugados de il-2 y métodos de uso para tratar enfermedades autoinmunes
MX2023000859A (es) Composiciones y metodos relacionados con agentes terapeuticos activables.
CL2020002915A1 (es) Composiciones para el tratamiento de condiciones de la piel
HN2011001195A (es) Compuestos que expanden las celulas madre hematopoieticas
MX2021009259A (es) Conjugados de il-2 y metodos de uso del mismo.
ECSP20046463A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
MX2018009917A (es) Vacuna contra el virus del zika.
CO2022010330A2 (es) Dosificación de gamma-hidroxibutirato (ghb)
CR20200545A (es) Inhibidores magl
MX2022001776A (es) Terapias de combinacion de inmuno oncologia con conjugados de il-2.
MX2021012051A (es) Vacunas para circovirus porcino tipo 3 (pcv3), y produccion y sus usos.
CO2023014622A2 (es) Conjugados de anticuerpo-fármaco anti-c-met
CO2022000481A2 (es) Inhibidores de enzimas
BR112022004397A2 (pt) Composições para tratamento bucal que compreendem beta ácidos de lúpulo e aminoácidos
CL2021002807A1 (es) Anticuerpos y métodos para el tratamiento de la infección por influenza a
DOP2023000219A (es) Compuestos de tienopirrol
CO2023004381A2 (es) Anticuerpos cd1a y su uso
MX2024002913A (es) Anticuerpos anti-siglec-6 y metodos de uso de los mismos.
MX2020010932A (es) Enzimas quinureninasa humanas y sus usos.
AR119979A1 (es) Anticuerpos contra el factor de las células madre y métodos de uso de ellas
MX2023007643A (es) Ensamblaje in vitro de cápsides de anellovirus que encierran arn.
MX2022012618A (es) Aptameros para uso en el tratamiento de infecciones por coronavirus.
CO2024005318A2 (es) Composiciones iluminadoras y métodos de uso
CU20100056A7 (es) Método para inhibir la replicación del vih en células de mamíferos